Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes.
Correlates of support for a nicotine-reduction policy in smokers with 6-week exposure to very low nicotine cigarettes.
复制标题
在6周暴露于非常低尼古丁香烟的6周的吸烟者中，对尼古丁减少政策的支持相关。
DOI：
10.1136/tobaccocontrol-2018-054622
复制
发表时间：
2019-05
期刊：
影响因子：
5.2
通讯作者：
Donny EC
中科院分区：
文献类型：
--
作者：
Denlinger-Apte RL;Tidey JW;Koopmeiners JS;Hatsukami DK;Smith TT;Pacek LR;McClernon FJ;Donny EC
The US Food and Drug Administration recently issued an advanced notice of proposed rulemaking for reducing the nicotine content in cigarettes to a minimally addictive level. Very little is known about whether use of very low nicotine content (VLNC) cigarettes affects support for a nicotine reduction policy. This study examined the effects of using VLNC versus usual brand (UB) cigarettes on support for a nicotine reduction policy and determined whether participant characteristics and responses to VLNC cigarettes were associated with policy support. Participants from a cigarette trial who were assigned to either 0.4 mg nicotine/g tobacco research cigarettes or their UB for 6 weeks were asked about their support for the policy. χ2 tests were used to compare support for the policy between cigarette conditions and logistic regression analyses were conducted to assess covariates associated with policy support. Policy support did not differ by condition. After 6 weeks of using VLNC cigarettes, 50% of participants supported the policy, 26% opposed and 24% responded ’Don’t Know’. Support was higher among those adherent to smoking only VLNC cigarettes (65%) compared with those who were non-adherent (44%). Older participants and those interested in quitting had increased odds of support. Cigarette satisfaction, perceived harm and perceived nicotine content were not significantly associated with support. Smoking VLNC cigarettes did not affect support for a nicotine reduction policy. Understanding predictors of policy support and opposition will help public health officials to maximise the public health acceptance and impact of this policy (ClinicalTrials. gov Identifier: NCT01681875 Post-Results).
登录
查看更多内容
影响因子：
5.2
作者：
Kozlowski LT
通讯作者：
Kozlowski LT
影响因子：
25.8
作者：
Higgins, Stephen T.;Heil, Sarah H.;Tursi, Lauren
通讯作者：
Tursi, Lauren
DOI：
10.1056/nejmsa1502403
发表时间：
2015-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Donny EC;Denlinger RL;Tidey JW;Koopmeiners JS;Benowitz NL;Vandrey RG;al'Absi M;Carmella SG;Cinciripini PM;Dermody SS;Drobes DJ;Hecht SS;Jensen J;Lane T;Le CT;McClernon FJ;Montoya ID;Murphy SE;Robinson JD;Stitzer ML;Strasser AA;Tindle H;Hatsukami DK
通讯作者：
Hatsukami DK
DOI：
10.3390/ijerph15010072
发表时间：
2018-01-05
影响因子：
--
作者：
Schmidt AM;Kowitt SD;Myers AE;Goldstein AO
通讯作者：
Goldstein AO
影响因子：
5.2
作者：
Bolcic-Jankovic, Dragana;Biener, Lois
通讯作者：
Biener, Lois